News of Note—Heplisav-B sales; Janssen’s therapeutic HPV vaccine and more

Emergent BioSolutions reported fourth-quarter revenues of $270.7 million. (Pixabay)

Here is some other vaccine news of note for the week:

> Dynavax’s Heplisav-B has been off to a slow start. Launched in the U.S. last January, the hepatitis B vaccine pulled in $3.9 million in fourth-quarter revenue, up from $1.5 million in the third quarter. Competition is close behind, as VBI Vaccines is comparing its Sci-B-Vac to GlaxoSmithKline’s Engerix B in phase 3 studies and expects topline readouts in 2019. Dynavax release | VBI release

> Janssen and Bavarian Nordic have officially started a phase 1/2a study evaluating a prime-boost therapeutic vaccine regimen for early treatment and interception of HPV-induced cancers. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Athanasios Papadopoulos, M.D., most recently a Sanofi executive who played a critical role in the development of Dengvaxia, has been appointed as Emergex Vaccines’ chief medical officer. Release

> Emergent BioSolutions reported fourth-quarter revenues of $270.7 million, boosted by some recently acquired products such as opioid overdose-reversing drug Narcan, typhoid vaccine Vivotif and cholera vaccine Vaxchora. Release

> Valneva’s sales grew 16% in 2018 at constant exchange rates, reaching €103.5 million ($117.8 million). The company now expects sales in 2019 of between €115 million and €125 million. Release

> Batavia Biosciences received a $13.2 million grant from the Bill & Melinda Gates Foundation to make inactivated polio vaccines based on its newly developed low-cost manufacturing process known as HIP-IPV. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.